{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravenous+immunoglobulins+%28IVIG%29",
    "query": {
      "intervention": "Intravenous immunoglobulins (IVIG)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 221,
    "total_pages": 23,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravenous+immunoglobulins+%28IVIG%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T16:08:53.740Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03749096",
      "title": "Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person Syndrome",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stiff-Person Syndrome"
      ],
      "interventions": [
        {
          "name": "Intravenous Immunoglobulins, Human",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-12-07",
      "completion_date": "2019-04-26",
      "has_results": false,
      "last_update_posted_date": "2019-06-13",
      "last_synced_at": "2026-10-04T16:08:53.740Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03749096"
    },
    {
      "nct_id": "NCT00110708",
      "title": "Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism",
        "Autistic Disorder",
        "Child Development Disorders, Pervasive",
        "Gastrointestinal Diseases",
        "Signs and Symptoms, Digestive"
      ],
      "interventions": [
        {
          "name": "Oralgam (human immunoglobulin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PediaMed Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 120,
      "start_date": "2005-04",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2006-02-22",
      "last_synced_at": "2026-10-04T16:08:53.740Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00110708"
    },
    {
      "nct_id": "NCT01399593",
      "title": "Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Antibody Mediated Rejection"
      ],
      "interventions": [
        {
          "name": "Eculizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2011-11-02",
      "completion_date": "2015-11-13",
      "has_results": true,
      "last_update_posted_date": "2017-10-03",
      "last_synced_at": "2026-10-04T16:08:53.740Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01399593"
    },
    {
      "nct_id": "NCT00278954",
      "title": "Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immunodeficiency",
        "Common Variable Hypogammaglobulinemia",
        "X-linked Hypogammaglobulinemia",
        "Hypogammaglobulinemia",
        "Immunodeficiency With Hyper-IgM",
        "Wiskott-Aldrich Syndrome"
      ],
      "interventions": [
        {
          "name": "Gammaplex (Intravenous immunoglobulin)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bio Products Laboratory",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2006-01",
      "completion_date": "2007-11",
      "has_results": true,
      "last_update_posted_date": "2013-01-24",
      "last_synced_at": "2026-10-04T16:08:53.740Z",
      "location_count": 7,
      "location_summary": "North Palm Beach, Florida • Atlanta, Georgia • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "North Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Irving",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00278954"
    },
    {
      "nct_id": "NCT06637072",
      "title": "A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Inflammatory Demyelinating Polyneuropathy"
      ],
      "interventions": [
        {
          "name": "Efgartigimod PH20 SC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2024-12-10",
      "completion_date": "2026-02-19",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-10-04T16:08:53.740Z",
      "location_count": 13,
      "location_summary": "Washington D.C., District of Columbia • Maitland, Florida • Miami, Florida + 9 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Lafayette",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06637072"
    },
    {
      "nct_id": "NCT06752356",
      "title": "A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Inflammatory Demyelinating Polyneuropathy"
      ],
      "interventions": [
        {
          "name": "Immune globulin (human) 10% solution for intravenous administration",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Kedrion S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 161,
      "start_date": "2026-10",
      "completion_date": "2027-12-27",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-10-04T16:08:53.740Z",
      "location_count": 5,
      "location_summary": "Stamford, Connecticut • Miami, Florida • Tampa, Florida + 2 more",
      "locations": [
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "El Paso",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06752356"
    },
    {
      "nct_id": "NCT03829566",
      "title": "Autologous Transplant To End NMO Spectrum Disorder",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Neuromyelitis Optica",
        "Devic's Disease",
        "NMO Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "rATG",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "IVIg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous Stem Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2019-11",
      "completion_date": "2025-11-28",
      "has_results": false,
      "last_update_posted_date": "2019-11-20",
      "last_synced_at": "2026-10-04T16:08:53.740Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03829566"
    },
    {
      "nct_id": "NCT01628055",
      "title": "IVIG in Acute Ischemic Stroke: A Pilot Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "Privigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Inova Health Care Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "45 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2013-03",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2013-11-11",
      "last_synced_at": "2026-10-04T16:08:53.740Z",
      "location_count": 1,
      "location_summary": "Falls Church, Virginia",
      "locations": [
        {
          "city": "Falls Church",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01628055"
    },
    {
      "nct_id": "NCT05070455",
      "title": "An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Primary Immune Deficiency"
      ],
      "interventions": [
        {
          "name": "Asceniv™",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ADMA Biologics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "2 Years to 11 Years"
      },
      "enrollment_count": 12,
      "start_date": "2022-09-01",
      "completion_date": "2023-06-30",
      "has_results": false,
      "last_update_posted_date": "2022-09-16",
      "last_synced_at": "2026-10-04T16:08:53.740Z",
      "location_count": 3,
      "location_summary": "Centennial, Colorado • Charleston, South Carolina • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05070455"
    },
    {
      "nct_id": "NCT04859829",
      "title": "Autoimmune Gastrointestinal Dysmotility: Symptoms, Pathogenesis and Treatment",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Dysmotility Syndrome",
        "Autoimmunity"
      ],
      "interventions": [
        {
          "name": "Current Intravenous Immunoglobulin (IVIG) treatment",
          "type": "OTHER"
        },
        {
          "name": "No Intravenous Immunoglobulin (IVIG) treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2021-04-22",
      "completion_date": "2022-09-29",
      "has_results": false,
      "last_update_posted_date": "2023-03-13",
      "last_synced_at": "2026-10-04T16:08:53.740Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04859829"
    }
  ]
}